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SUMMARY
Background
Thiopurines (azathioprine and mercaptopurine) remain integral to most medical
strategies for maintaining remission in Crohn’s disease (CD) and ulcerative colitis
(UC). Indeﬁnite use of these drugs is tempered by long-term risks. While clinical
relapse is noted frequently following drug withdrawal, there are few published data
on predictive factors.
Aim
To investigate the success of planned thiopurine withdrawal in patients in
sustained clinical remission to identify rates and predictors of relapse.
Methods
This was a multicentre retrospective cohort study from 11 centres across the UK.
Patients included had a deﬁnitive diagnosis of IBD, continuous thiopurine use ≥3 years
and withdrawal when in sustained clinical remission. All patients had a minimum of
12 months follow-up post drug withdrawal. Primary and secondary end points were
relapse at 12 and 24 months respectively.
Results
237 patients were included in the study (129 CD; 108 UC). Median duration of thiopu-
rine use prior to withdrawal was 6.0 years (interquartile range 4.4–8.4). At follow-up,
moderate/severe relapse was observed in 23% CD and 12% UC patients at 12 months,
39% CD and 26% UC at 24 months. Relapse rate at 12 months was signiﬁcantly higher
in CD than UC (P = 0.035).
Elevated CRP at withdrawal was associated with higher relapse rates at 12 months
for CD (P = 0.005), while an elevated white cell count was predictive at 12 months
for UC (P = 0.007).
Conclusion
Thiopurine withdrawal in the context of sustained remission is associated with a 1-year
moderate-to-severe relapse rate of 23% in Crohn’s disease and 12% in ulcerative colitis.
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INTRODUCTION
Thiopurines have been in clinical use for 50 years and
remain the backbone of maintenance strategies for IBD,
either as monotherapy or in combination with an anti--
tumour necrosis factor agent.1 Azathioprine (AZA) and
its metabolite mercaptopurine (MP) are effective in
maintaining clinical remission in patients with Crohn’s
disease (CD) and ulcerative colitis (UC).2–8 Around 10–
28% of patients report side effects (most commonly nau-
sea) of which 50–80% will discontinue the drug as a
result.9, 10 Thiopurines have a narrow therapeutic win-
dow and carry a risk of dose-dependent myelosupres-
sion4, 9, 11, 12 and hepatotoxicity.10, 13 A subset of the
population who carry two loss of function thiopurine
methyltransferase (TPMT) alleles have the greatest risk
of myelosupression and serious adverse events.14 Contin-
uous use of thiopurines has also been linked with malig-
nancies such as lymphoma and non-melanoma skin
cancer.15, 16 A large prospective study of 19 486 IBD
patients showed incidence rates of non-melanoma skin
cancer for current and previous AZA use at 0.66/1000
and 0.38/1000 patient years respectively (age < 50) and a
cumulative increase with age.15 Beaugerie showed an
incidence rate of 0.9/1000 patient years for lymphoma in
those receiving AZA (n = 19 486), casting doubt on its
long-term safety.16 These long-term risks make clinicians
and patients wary about indeﬁnite use of thiopurines
despite the risk of relapse on withdrawal.
The relapse rates after stopping thiopurines have been
reported in CD at 21–41% at 1 year with a cumulative
increase to 61–85% at 5 years.3, 17–21 In UC, one rando-
mised controlled trial and three retrospective studies
showed relapse rates of 35–77% at 1 year and 65–75% at
5 years.9, 22–24 However, most of these studies had
patients on treatment for a short period of time
(Table 1) and perhaps therefore overestimate the risk of
disease relapse in patients who are in sustained clinical
remission.
We aimed to examine relapse rates following thiopu-
rine withdrawal along with predictive factors and the
success of recapture in a large group of patients with at
least 3 years of continuous thiopurine therapy for CD or
UC.
METHODS
Study design
A retrospective multi-centre clinical audit was performed
with patients identiﬁed from 11 IBD centres across the
UK. Detailed case note review was performed in all
patients using a standardised, pre-designed proforma.
Data were collected for patient demographics including
age, sex, weight, smoking status, age at diagnosis and
date of diagnosis. Details of drug therapy included the
type of thiopurine used, start date, initial dose and maxi-
mum dosage, age at withdrawal and any dose tapering at
withdrawal, plus concomitant medications. Details of
parameters at withdrawal included Montreal classiﬁca-
tion and behaviour, laboratory markers [C-reactive pro-
tein (CRP), haemoglobin, white cell count, platelets,
albumin], endoscopic ﬁndings and reasons for with-
drawal. Relapse was recorded including any change in
drug therapy or reintroduction of thiopurines. Patients
were identiﬁed by searching IBD databases and/or clinic
lists of those attending out-patient IBD clinics to reduce
the risk of bias from physicians recalling only those
patients who had relapsed.
Inclusion criteria
Patients had a deﬁnitive diagnosis of UC or CD and
continuous thiopurine use for at least 35 months. They
were in clinical remission at the time of drug withdrawal
as deﬁned by physician global assessment and no use of
corticosteroids within the preceding 6 months. The min-
imum follow-up time following withdrawal was
12 months (or moderate–to-severe relapse within
12 months). Patients were excluded if they were on con-
comitant anti-TNF therapy at the point of thiopurine
withdrawal.
Disease relapse was deﬁned by severity and categor-
ised as mild, moderate or severe. Mild relapse was
deﬁned by the use of topical treatments or commence-
ment or dose increase of oral 5-aminosalicylate (5-ASA)
while moderate relapse was deﬁned by the use of oral
steroids or recommencement of thiopurine. Admission
to hospital, surgery, use of intravenous corticosteroids or
commencement of anti-TNF was considered a severe
relapse.
At study design, primary end-point was deﬁned as
moderate-to-severe relapse at 12 months while secondary
end-point was moderate-to-severe relapse at 24 months.
Statistical analysis
Data were analysed using Microsoft Excel 2010 (Micro-
soft, Redmond, WA, USA) and R 3.1.1 (R Foundation
for Statistical Computing, Vienna, Austria). Continuous
data are presented as medians and interquartile ranges
and were analysed using a Mann–Whitney U-test. Cate-
gorical data are presented as numbers and percentages
and were analysed using v2 or Fisher’s exact tests as
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appropriate. Survival analysis was done using Kaplan–
Meier analysis in the survival package in R. Patients was
censored at the point of most recent follow-up. Estimates
of relapse rates for each severity category over time were
generated from the overall survival function and the pro-
portion of relapses of that category to that time point.
For analysis of predictive factors, each factor was analy-
sed in those patients for whom those data were available.
Patients with additional reasons for withdrawal that
could potentially have inﬂuenced laboratory parameters
were excluded from analysis of these parameters.
Multivariable analysis was performed using Cox Pro-
portional Hazards. Backward stepwise regression was
used to select variables for the ﬁnal model. Variables that
did not lead to a lower Akaike information criterion
(AIC) were excluded in a stepwise manner, and ﬁnally
variables whose hazard ratio had a 95% conﬁdence inter-
val that crossed one were excluded. Continuous data
were then converted to categorical data by ﬁnding the
thresholds that gave the lowest AIC for the ﬁtted model.
RESULTS
Across all centres, 264 patients were submitted. 27 were
excluded, for reasons detailed in Table S1, leaving 237
patients, 129 with CD and 108 with UC, in the primary
analysis (Table 2; breakdown by study centre in Table
S2). The median duration of thiopurine use prior to drug
withdrawal was 6.0 years (IQR 4.4–8.2) for CD and
5.8 years (IQR 4.5–8.5) for UC. The median follow-up
post drug withdrawal in those without relapse was
32 months (IQR 24–51) for CD and 36 months (IQR
21–52) for UC. Median CRP was 4.0 mg/L (IQR 2.5–
6.0) in CD and 2.5 mg/L (IQR 2.5–4.0) in UC (Table 3).
All patients were in sustained clinical remission at the
time of thiopurine withdrawal; 35/237 (22 CD; 13 UC)
had an additional trigger for drug cessation (Table S3).
Table 1 | Summary of AZA/6MP withdrawal studies
Study
Design
Study cohort
Number of
patients
studied
following
thiopurine
withdrawal Drug
Duration of
thiopurine
(months)
Follow-up
(months) Relapse rate
Factors
predictive
of relapse
O’Donoghue
(1978)3
RCT
CD
51 AZA >24 6 1 year: Control
41%; AZA 5%
Lemmann
(2005)19
RCT
CD
43 AZA >42 18 18 months:
Control 21.3%;
AZA 7.9%
CRP
Hb
Time without steroids
Bouhnik
(1996)17
Retrospective
CD
42 AZA
or
MP
31 (median) 60 1 year: 38%
3 years: 61%
5 years: 75%
Male gender
Age <31 years
Remission<4 years
Kim
(1999)20
Audit
CD
36 MP >6 60 1 year: 36%
2 years: 71%
≥3 years: 85%
Younger age
Higher dose of 6MP during
remission
Treton
(2009)18
Open label
CD
66 AZA 68 (median) 60 1 year: 14%
3 years: 52.8%
5 years: 62.7%
CRP ≥20 g/L
Hb <120 g/L
Neutrophils ≥4.0 9 109/L
Fraser
(2002)9
Retrospective
case series
CD and UC
CD – 79
UC – 143
AZA 24 (mean) 60
1 year:
3 years:
5 years:
CD/UC
37%/37%
66%
75%/75%
Sokol
(2010)31
Audit
CD
47 AZA >42 60 2 years: 57%
5 years: 73.3%
Male
Non-smoking
Hawthorne
(1992)24
RCT
UC
34 AZA 21 (mean) 12 1 year: Control
59%; AZA 35%
Lobel
(2004)22
Retrospective
review
UC
22 MP 45 (median) 40 1 year: 77%
2 years: 100%
Cassinotti
(2009)23
Retrospective
review
UC
127 AZA 47 (median) 60 1 year: 35%
3 years: 59%
5 years: 65%
Shorter duration of
AZA (in remission)
Aliment Pharmacol Ther 3
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Thiopurine withdrawal in IBD
Thiopurines were tapered prior to withdrawal in 87
patients (37%). Data on length of taper were available in
48 of these patients, with a median duration of 12 weeks
(IQR 8–26).
Disease relapse and predictive factors: univariable
analysis
23% of CD patients had a moderate-to-severe relapse
within 12 months of thiopurine withdrawal as compared
to 12% in UC patients (Figure 1). There was a signiﬁcant
difference in survival without moderate-to-severe relapse
between CD and UC assessed by logrank test
(P = 0.035). CRP at time of drug withdrawal was associ-
ated with signiﬁcantly greater relapse in CD within
12 months (P = 0.005) but was not predictive in UC
(Table 4). Relapse at 12 months in CD was also associ-
ated with having tapered the thiopurine at withdrawal
(P = 0.004). In the UC cohort, white cell counts at with-
drawal were signiﬁcantly higher in those who relapsed
by 12 months (P = 0.007), although the upper quartile
was still in the normal range.
Multivariable analysis
Disease location and the most signiﬁcant univariable lab-
oratory parameters (haemoglobin, white cell count and
CRP) were included in multivariable models for CD and
UC. The Cox proportional hazards method was used to
create a model to assess the contribution of each variable
to risk of relapse. After backwards stepwise exclusion of
variables that did not contribute to the model, WCC and
CRP remained for CD, and only WCC remained for UC
(Table 5). Thresholds were then found to allow stratiﬁca-
tion of patients at higher and lower risk, and to allow
creation of survival curves (Figure 2).
Consequences of relapse
Among all CD patients, by 12 months, 23 patients (18%)
had required systemic corticosteroids, four patients (3%)
had required anti-TNF therapy, seven patients (5%) had
required hospital admission and ﬁve patients (4%) had
required resectional surgery. Among all UC patients, by
12 months, six patients (6%) had required systemic
steroids, one patient (1%) hospitalisation and no patient
Table 2 | Study demographics, Montreal classiﬁcation and disease behaviour for patients in clinical remission on
thiopurines
Variable Crohn’s disease, n = 129 Ulcerative colitis, n = 108
Females (%) 76 (59.8%) 42 (39.6%)
Median (IQ range) age at withdrawal/years 38 (28–48) 42 (33–58)
Current smokers (%)* 23 (19.2%) 4 (4.3%)
Median (IQR) duration thiopurine use/years 6.0 (4.4–8.2) 5.8 (4.4–8.5)
Range duration thiopurine use/years 2.9–18.7 2.9–18.0
Median (IQR) peak AZA dose/mg 125 (100–150) 150 (112–150)
Median (IQR) duration follow-up in those
without relapse/months
31.7 (23.9–50.8) 36.0 (20.6–52.2)
Median year stopped AZA (range) 2008 (1980–2012) 2008 (1999–2011)
Montreal location†
L1  L4 29/123 (23.6%)
L2  L4 48/123 (39.0%)
L3  L4 44/123 (35.8%)
L4 2/123 (1.6%)
Montreal behaviour†
B1 88/123 (71.5%)
B2 16/123 (13.0%)
B3 19/123 (15.4%)
Montreal extent‡
E1 23/97 (23.7%)
E2 26/97 (26.8%)
E3 48/97 (49.5%)
5ASA at time of withdrawal 40 (31.0%) 83 (76.1%)
* Smoking status unknown in 23 patients.
† Montreal location and behaviour unknown in six patients
‡ Montreal extent unknown in 11 patients.
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required anti-TNF or resectional surgery. By the end of
follow-up, a further three CD and two UC patients had
required resectional surgery, although this was for dys-
plasia in one of the UC cases.
Within the 48 CD patients with a moderate-to-severe
relapse at any point and did not require surgery or
anti-TNF, 42 (88%) had a thiopurine re-introduced. Of
those, reintroduction was successful in 31 (74%)
Table 3 | Blood parameters for Crohn’s disease and ulcerative colitis cohort at the time of thiopurine withdrawal
Test
Crohn’s disease Ulcerative colitis
Number of patients Median (IQR) Number of patients Median (IQR)
Haemoglobin (g/L)* 107 150 (141–158) 94 148 (140–155)
White cell count (109/L) 107 6.4 (5.3–8.4) 94 6.0 (4.8–7.0)
Platelets (109/L) 105 266 (220–343) 92 260 (213–312)
CRP (mg/L) 81 4.0 (2.5–6.0) 65 2.5 (2.0–4.0)
Faecal calprotectin (lg/g) 6 36 (27–71) 2 71 (56–86)
Albumin (g/L) 87 43 (41–46) 73 45 (42–47)
Hb, Haemoglobin; WCC, White cell count; Plt, Platelets; CRP, C-reactive protein.
* Hb for females was scaled to male range to allow for comparison across sexes.
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Figure 1 | Survival analysis of
relapse following withdrawal
of thiopurines for sustained
remission of Crohn’s disease
(a) and ulcerative colitis (b).
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Table 4 | Factors assessed against moderate-to-severe relapse by 12 months and diagnosis
Crohn’s disease Ulcerative colitis
No relapse by
12 months
Relapse by
12 months P
No relapse by
12 months
Relapse by
12 months P
Female sex 62/96 (64.6%) 14/29 (48.3%) 0.174 34/90 (37.8%) 6/13 (46.2%) 0.783
Smoking status at withdrawal
Current 17/92 (18.5%) 6/27 (22.2%) 0.366 4/82 (4.9%) 0/10 (0.0%) 0.825
Ex 15/92 (16.3%) 7/27 (25.9%) 24/82 (29.3%) 4/10 (40.0%)
Never 60/92 (65.2%) 14/27 (51.9%) 54/82
(65.9%)
6/10 (60.0%)
Age at diagnosis 24.0 (18.3–31.8) 25.5 (19.2–35.1) 0.587 28.0 (22.5–44.2) 28.0 (19.3–41.0) 0.586
Age when starting
thiopurine
29.0 (21.3–41.0) 30.0 (22.5–43.0) 0.988 36.0 (26.5–52.5) 35.0 (27.0–44.0) 0.723
Additional reason
for withdrawal
19/98 (19.4%) 2/29 (6.9%) 0.156 10/92 (10.9%) 2/13 (15.4%) 0.642
Maximum dose by
weight (mg/kg)
1.8 (1.5–2.2) 1.9 (1.6–2.2) 0.39 1.9 (1.7–2.1) 2.1 (2.0–2.2) 0.101
Tapered at withdrawal 27/98 (27.6%) 17/29 (58.6%) 0.004 34/92 (37.0%) 7/13 (53.8%) 0.387
5ASA at withdrawal 26/98 (26.5%) 12/29 (41.4%) 0.193 71/92 (77.2%) 9/13 (69.2%) 0.504
Montreal location
L1  L4 25/94 (26.6%) 4/27 (14.8%) 0.096
L2  L4 30/94 (31.9%) 16/27 (59.3%)
L3  L4 37/94 (39.4%) 7/27 (25.9%)
Pure L4 2/94 (2.1%) 0/27 (0.0%)
Montreal behaviour
B1 66/93 (71.0%) 20/28 (71.4%) 1.000
B2 12/93 (12.9%) 4/28 (14.3%)
B3 15/93 (16.1%) 4/28 (14.3%)
Montreal extent
E1 19/85 (22.4%) 4/10 (40.0%) 0.276
E2 22/85 (25.9%) 3/10 (30.0%)
E3 44/85 (51.8%) 3/10 (30.0%)
Haemoglobin (g/L)* 151 (145–159) 143 (139–154) 0.101 149 (139–155) 145 (140–151) 0.496
White cell count (9109/L) 6.2 (5.3–8.2) 7.6 (5.5–8.6) 0.270 5.9 (4.7–6.8) 7.7 (6.5–9.4) 0.007
Platelets (9109/L) 265 (220–316) 268 (226–375) 0.303 260 (213–312) 290 (250.5–324) 0.218
CRP (mg/L) 4.0 (2.1–6.0) 7.0 (3.8–16.5) 0.005 2.5 (2.0–4.0) 3.0 (2.8–4.5) 0.286
Albumin (g/L) 44.0 (41.0–46.0) 43.0 (41.0–45.0) 0.259 45.0 (42.2–47.0) 44.0 (41.0–45.0) 0.187
* Haemoglobin for females scaled to male range to allow comparison across sexes.
P values less than 0.05 are highlighted in bold.
Table 5 | Multivariable analysis of predictive factors for relapse following thiopurine withdrawal: ﬁnal Cox proportional
hazards model. (a) Crohn’s disease; (b) Ulcerative colitis
Analysis as continuous variables Analysis as categorical variables
Variable
Hazard ratio
(95% conﬁdence
interval) P-value
Optimum
threshold to
split data
Hazard ratio
when split by
threshold (95% CI)
P-value when
split by threshold
(a)
White cell count 1.18 (1.04–1.33) 0.011 ≥6.6 9 109/L 3.75 (1.87–7.54) 0.0002
C-reactive protein 1.04 (1.00–1.07) 0.035 ≥14 g/L 3.2 (1.48–7.05) 0.003
(b)
White cell count 1.44 (1.11–1.87) 0.007 ≥9.1 9 109/L 6.70 (1.86–24.2) 0.004
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Figure 2 | Survival analysis of relapse following withdrawal of thiopurines for sustained remission stratiﬁed by
predictive factors in Crohn’s disease (a) and ulcerative colitis (b).
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although the majority (21/31, 68%) also required sys-
temic steroids to reinduce remission. For UC patients,
thiopurines were reintroduced in 24 of 34 (71%) patients
with a moderate-to-severe relapse not requiring surgery
or anti-TNF. This was successful in 22 patients (92%),
with 11 (50%) requiring systemic steroids also.
DISCUSSION
In patients with CD, our study shows a moder-
ate-to-severe relapse rate of 24% at 1 year and 39% at
2 years after thiopurine withdrawal. This is similar to
published series showing a relapse rate of 21–41% with a
cumulative increase in the rate with time (Table 1). In
addition, our study demonstrates a signiﬁcant greater
relapse rate in CD patients compared to UC. While this
study does not address the rate of ﬂare in those contin-
uing therapy, a recent meta-analysis showed that the
odds ratio of a ﬂare in those stopping azathioprine ver-
sus those continuing was 0.15 [95% Conﬁdence Interval
(CI) 0.05–0.44] at 12 months and 0.30 (95% CI 0.08–
1.23) at 18 months.25
Previous studies have shown that CRP of 20 mg/L or
higher, a neutrophil count of 4.0 9 109/L, a haemoglo-
bin (<12 g/dL), male gender, age ≤31 and duration of
remission less than four years were factors predictive of
relapse.17, 18 However, duration of AZA/MP use and the
deﬁnition of remission varied with each study making it
difﬁcult to compare their study outcomes. Fraser et al.,
with n = 222 patients (79 CD, 143 UC), found no corre-
lation between disease ﬂare and clinical or laboratory
indices.9 Our study shows that CRP is highly predictive
of relapse in this cohort, a ﬁnding similar to Lemann
et al.19 Tapering of thiopurine prior to withdrawal was
also noted here to be associated with relapse, but practice
with relation to tapering was quite different between the
included centres and it is likely the observed differences
in relapse rates relate to other, unmeasured factors rather
than tapering itself.
In patients with UC, our study showed a lower relapse
rate of 11% at 12 months and 21% at 24 months. This
contrasts with a relapse rate after drug withdrawal in
other published studies as high as 35–77% at 1 year and
65–75% at 5 years (Table 1). We used strict criteria to
deﬁne sustained remission which included continuous
thiopurine use for a minimum ≥3 years and subsequent
withdrawal when in sustained clinical remission (absence
of symptoms and no corticosteroids for >6 months).
This will have impacted the subsequent relapse rates.
In the UC cohort, our study shows that a raised white
cell count is highly predictive of a relapse after drug
withdrawal. Hawthorne et al. performed a small RCT
trial and found younger age to be the statistically sig-
niﬁcant predictive factor for relapse.24 Cassinoti et al.
performed a multicentre observational study of 127 UC
patients and found that relapse during treatment with
AZA, withdrawal of AZA due to drug toxicity and dis-
ease extent to be predictive of disease relapse at drug
withdrawal. Patients in this study had concomitant
aminosalicylates, masking the true effects of AZA.23
On the contrary, a large single centre study with 143
UC patients did not show any factors predictive of
relapse.9
The deﬁnition of clinical remission is important when
evaluating drug withdrawal studies. Studies have used
various clinical disease activity indices and laboratory
markers to deﬁne clinical remission. Two randomised
controlled trials used the Crohn’s Disease Activity Index
(CDAI),19, 21 while others used the Harvey Bradshaw
Index (HBI).9, 17, 20 O’Donoghue et al. and Lobel et al.
utilised the Physician Global Assessment (PGA) score to
deﬁne remission and disease ﬂare in CD.3, 22 We used
the PGA clinical index and corticosteroid use (in the last
6 months) to deﬁne remission.
Recapture data have only been reported by Treton
et al. in CD patients where 22 of the 23 patients were
successfully retreated with AZA.18 Although a small
cohort, our study is the only study to show retreatment
success in both disease groups. However, it should be
noted that 25/29 patients with CD and moder-
ate-to-severe relapse within 12 months (20% of the over-
all CD cohort) required systemic steroids, anti-TNF or
hospital admission and ﬁve of these patients required re-
sectional surgery. Further large studies are needed to
ascertain re-treatment success as this would have an
impact on our decisions to withdraw thiopurines.
With high cumulative relapse rates after thiopurine
withdrawal in sustained remission, devising a set of key
relapse indicators that encompass clinical, endoscopic
and laboratory markers would be beneﬁcial. Our study
highlights the importance of risk stratiﬁcation in
patients before considering drug withdrawal. The
knowledge of these predictive factors may be translated
onto the anti-TNF group of patients; however, multi-
centre trials are required to validate this. The STORI
study, looking at inﬂiximab withdrawal in CD remission
showed that the presence of no more than two risk fac-
tors (a combination of clinical and biological markers)
carried a 15% risk of relapse at 1 year.26 Similarly, risk
stratiﬁcation in patients on long-term AZA/MP
treatment who are risk of disease ﬂare post drug
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withdrawal can be adopted in clinical practice. Future
studies could use pre-deﬁned risk groups to assess
relapse rates post drug withdrawal.
In addition to risk factors for disease relapse, adverse
events with long-term use must be taken into account
when considering drug withdrawal. The small but deﬁ-
nite association of non-melanoma skin cancer and lym-
phoma with long-term thiopurine use has been
reported.15, 16 The risk of non-melanoma cancer is
greater when treating older patients with IBD.15 In addi-
tion, the comorbidity rate is signiﬁcantly higher in the
elderly group (age >65 years) with IBD.27, 28 With an
ageing population worldwide, the number of older
patients with IBD is also expected to increase.29 There-
fore, treatment strategies with thiopurines would need
further evaluation and a careful consideration.
The key strengths of our study are threefold. Our
study is one of the largest to date looking at AZA/MP
withdrawal. While many studies used varied parameters
to deﬁne remission, we used strict clinical parameters
with at least 3 years of continuous thiopurine use prior
to drug withdrawal.
Patients within this study were selected for withdrawal
by their physicians on the basis of their assessment, and
so the withdrawal rates may not be generalisable to all
patients in clinical remission. For example, physicians
may have been less likely to withdraw patients with peri-
anal disease or rectal disease. There were also limited
data available on faecal calprotectin; it is likely that as an
accurate marker of endoscopic disease activity30 it would
prove highly useful in predicting relapse in this context,
as has been seen for inﬂiximab withdrawal in the STORI
study.26 The study may have been underpowered to
fully assess the predictive power of all of the factors
assessed.
Thiopurines remain an integral part of disease man-
agement in IBD patients with evidence of its role in sus-
taining long-term remission. However, bearing in mind
the side effects and risks of malignancy with long-term
immunosuppression, it is crucial to identify a sub-cohort
who are at highest risk of disease ﬂare. Our study and
data from the STORI trial suggest that patients in clini-
cal and biochemical remission have a low risk of relapse.
Of those who relapse after drug withdrawal, reintroduc-
tion of thiopurines allows recapture in the majority of
IBD patients, particularly in UC. However, in a select
group of patients (CD cohort), long-term thiopurines
may be in their best interest, especially if the conse-
quences of disease ﬂare have an impact on morbidity
and subsequent remission rates.
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